Bayer establishes Cell and Gene Therapy Platform

Opinions

Date: 22.04.2021

Bayer AG announced the launch of a Cell and Gene Therapy (C&GT) Platform within its Pharmaceuticals division. Through this strategic platform, the company further consolidates its emerging leadership in the field and takes a deeply transformative step for its business.

In order to build up its presence in C&GT, Bayer is strengthening its internal C&GT capabilities. At the same time, the company is pursuing external strategic collaborations, technology acquisitions and licensing.

The goal is to build robust platforms with broad application across different therapeutic areas. For example, Bayer has just acquired an industry-leading contract manufacturing organization in gene therapy. Together with Bayer’s expertise and recent investments in product supply capabilities, this will contribute to fill an important global demand gap for development and manufacturing of gene therapies.

Leveraging external innovation together with the expertise of the teams at Bayer represents a key value-driver, especially in the highly dynamic and competitive field of C&GT.

Based on: Bayer.com

#News #Health #Medical #Bayer #Whealthnews

Views: 32

Leave a request

Select option
Thank you, application submitted.